By Michael Phillips | The Thunder Report
President Donald Trump closed out the third week of December with a flurry of executive action and a headline-grabbing set of pharmaceutical agreements that the White House is framing as one of the most consequential cost-of-living wins of his second term. From space and national security to prescription drug prices and marijuana research, the past week underscored an administration focused on domestic policy delivery rather than new legislative battles.
Executive Orders: December 13–19, 2025
Reasserting American Space Superiority
On December 18, President Trump signed an executive order titled “Ensuring American Space Superiority,” placing space back at the center of U.S. national strategy. The order:
- Reaffirms U.S. leadership in space as a matter of national security and economic power.
- Directs reforms to slow and costly federal space acquisition processes.
- Accelerates development of next-generation missile defense technologies tied to the administration’s “Iron Dome for America” concept.
- Sets ambitious goals, including a return of U.S. astronauts to the Moon by 2028 and the early stages of a permanent lunar outpost by 2030.
- Revokes a Biden-era National Space Council directive, signaling a sharper, defense-oriented approach to space policy.
The order reflects Trump’s long-standing view that space dominance is inseparable from deterrence and technological leadership.
Marijuana Reclassification: Research Without Legalization
Another notable December 18 order directed the Justice Department and relevant agencies to expedite the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act.
- The move eases research restrictions and acknowledges potential medical uses, including pain management and opioid alternatives.
- It stops well short of nationwide legalization or endorsement of recreational use.
- The administration framed the action as pragmatic reform rather than cultural or ideological signaling.
For the cannabis industry and medical researchers, the order marks a meaningful regulatory shift while preserving federal limits.
Federal Holiday Closures
In a more routine but popular move, Trump signed an order closing most executive departments on December 24 and December 26, creating a five-day holiday break for many federal workers. Essential national security and emergency personnel were excluded.
Immigration and Security Proclamation
On December 16, the White House issued a proclamation expanding travel restrictions on nationals from certain high-risk countries, citing inadequate vetting and information-sharing. The administration characterized the move as a continuation of Trump’s security-first immigration posture rather than a broad travel ban.
The Headline Achievement: Drug Prices and TrumpRx
The most consequential development of the week came on December 19, when President Trump announced sweeping voluntary agreements with major pharmaceutical companies to sharply reduce prescription drug prices.
Pharmaceutical Deals: “Most Favored Nation” Pricing
The administration finalized agreements with nine major drugmakers, including firms such as Merck, Amgen, Bristol Myers Squibb, Sanofi, GSK, and Novartis (company lists vary slightly by source).
Key provisions include:
- Most-Favored-Nation pricing for Medicaid, requiring companies to match U.S. prices to the lowest available in other developed nations.
- Commitments that new drugs will not launch in the U.S. at prices higher than those charged abroad.
- Billions in projected savings for state and federal Medicaid programs.
Examples of price reductions cited by the administration:
- Advair Diskus (asthma inhaler): ~$265 → $89
- Januvia (diabetes): ~$330 → $100
- Repatha (cholesterol): ~$573 → $239
- Plavix (blood thinner): ~$756 → $16
- Insulin products: capped at $35 per month
The White House credited tariff leverage and trade pressure for helping secure the concessions, arguing that U.S. consumers have long subsidized global drug development costs.
TrumpRx.gov: Direct-to-Consumer Access
Central to the rollout is TrumpRx.gov, a new federal platform set for full launch in January 2026.
- The site connects patients directly to manufacturers’ discounted cash-pay offerings.
- It bypasses traditional intermediaries such as pharmacy benefit managers, which the administration has repeatedly blamed for opaque pricing.
- TrumpRx stems from a May 2025 executive order and has now become the public-facing vehicle for these price cuts.
Administration officials framed the initiative as structural reform rather than a temporary subsidy.
Investment and Manufacturing Commitments
Beyond price reductions, participating pharmaceutical companies pledged:
- More than $150 billion in combined U.S. manufacturing, research, and development investments.
- Donations of key active pharmaceutical ingredients to strengthen domestic reserves.
- Expanded U.S. production in exchange for faster regulatory reviews and potential tariff relief.
As of December 19, 14 of 17 targeted drugmakers have reportedly signed on, marking the largest wave of participation since negotiations began earlier in 2025.
No New Foreign Deals—By Design
Notably absent from the week were new international agreements or headline foreign investment announcements. Instead, the administration emphasized execution on existing priorities rather than symbolic diplomacy. Officials indicated that trade and security negotiations remain ongoing but were not the focus of this December push.
The Bigger Picture
The past week reinforced a clear governing theme for the Trump White House in late 2025: deliver tangible domestic outcomes without waiting on Congress. Space policy, drug pricing, regulatory reform, and national security actions all fit within that framework.
Whether the pharmaceutical agreements hold over the long term will be closely watched. For now, the administration is betting that visible price cuts and a direct-to-consumer model will resonate with voters more than abstract policy debates.
As Trump heads into the final weeks of the year, the message from the West Wing is unmistakable: results first, politics second.
Keep This Reporting Free
If this work matters to you, please consider supporting it.
Your contribution helps fund independent reporting across our entire network.
Discover more from RIPTIDE
Subscribe to get the latest posts sent to your email.
